Mustang Bio, Inc. (MBIO) |
|
0.3666 -0.016 (-4.28%)
|
03-31 16:00 |
|
Open: |
0.394 |
Pre. Close: |
0.383 |
|
High:
|
0.394 |
Low:
|
0.3544 |
|
Volume:
|
370,807 |
Market Cap:
|
40(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:20:20 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.56  One year: 0.67 |
| Support: |
Support1: 0.34 Support2: 0.28 |
| Resistance: |
Resistance1: 0.48 Resistance2: 0.57 |
| Pivot: |
0.37 |
| Moving Average: |
MA(5): 0.36  MA(20): 0.39
MA(100): 0.5 MA(250): 0.58 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 23.9 %D(3): 18.5 |
| RSI: |
RSI(14): 35.7 |
| 52-week: |
High: 1.09 Low: 0.31 |
| Average Vol(K): |
3-Month: 404 (K) 10-Days: 274 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MBIO ] has closed above bottom band by 42.3%. Bollinger Bands are 64.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.39 - 0.4 |
0.4 - 0.4 |
|
Low:
|
0.35 - 0.35 |
0.35 - 0.35 |
|
Close:
|
0.36 - 0.37 |
0.37 - 0.37 |
|
Company Description |
|
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. |
Headline News |
Thu, 30 Mar 2023
Fortress Biotech Reports Record 2022 Financial Results and Recent ... - GlobeNewswire
Wed, 29 Mar 2023
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights - Yahoo Finance
Tue, 17 Jan 2023
Mustang Bio to Participate in the B. Riley Securities' 3rd - GlobeNewswire
Mon, 19 Dec 2022
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and ... - GlobeNewswire
Mon, 14 Nov 2022
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights - Yahoo Finance
Thu, 27 Oct 2022
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
106 (M) |
| Shares Float |
81 (M) |
|
% Held by Insiders
|
23.4 (%) |
|
% Held by Institutions
|
13.7 (%) |
|
Shares Short
|
292 (K) |
|
Shares Short P.Month
|
418 (K) |
Stock Financials |
|
EPS
|
-1.15 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.37 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-39.5 |
|
Return on Equity (ttm)
|
-83.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.7 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-64 (M) |
|
Levered Free Cash Flow
|
-47 (M) |
Stock Valuations |
|
PE Ratio
|
-0.33 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.26 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.61 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
